Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 5Terminated 2Withdrawn 1Temporarily not available 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rare Diseases 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms, Bone Tissue 1Neoplasms by Histologic Type 1Neoplasms 1Melanoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × FANG vaccine × Clear all
NCT03495921 2023-04-26

VITA

Gradalis, Inc.

Phase 3 Terminated
32 enrolled 13 charts
Sarcoma

Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective Tissue, Sarcoma, Sarcoma, Ewing, Neoplasms, Connective and Soft Tissue, Neoplasms, Bone Tissue, Neuroectodermal Tumors, Primitive, Peripheral, Rare Diseases

NCT00003715 2015-12-03

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

AVAX Technologies

Phase 2 Terminated
425 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡